RLAY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
350.0K
-88.3%
3.0M
-57.1%
7.0M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
350.0K
-88.3%
3.0M
-57.1%
7.0M
0
Operating Expenses
90.2M
-1.0%
91.2M
+11.7%
81.6M
+20.6%
67.6M
-15.9%
80.4M
R&D
77.1M
+0.9%
76.5M
+8.4%
70.6M
+27.3%
55.4M
-18.8%
68.3M
SG&A
13.1M
-10.8%
14.7M
+33.2%
11.0M
-9.7%
12.2M
+0.7%
12.1M
Operating Income
-90245000
+0.6%
-90824000
-15.6%
-78590000
-29.6%
-60630000
+24.6%
-80391000
EBITDA
-89965000
+0.6%
-90464000
-15.9%
-78086000
-30.1%
-60031000
+24.6%
-79643000
Net Income
-81745000
+2.3%
-83707000
-14.2%
-73291000
-33.5%
-54890000
+26.0%
-74149000
EPS (Basic)
$-0.37
+9.8%
$-0.41
+0.0%
$-0.41
-28.1%
$-0.32
+25.6%
$-0.43
EPS (Diluted)
$-0.37
+9.8%
$-0.41
+0.0%
$-0.41
-28.1%
$-0.32
+25.6%
$-0.43
Shares (Diluted)
219.2M
+8.0%
202.8M
+12.8%
179.8M
+3.7%
173.5M
+0.6%
172.4M
Relay Therapeutics (RLAY) — Financials